★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

Checking

Stock Profile

Halma plc (HLMA) Moat Analysis

Halma plc

HLMA · London Stock Exchange

Market cap (USD)$19.8B
SectorTechnology
IndustryConglomerates
CountryGB
Data as of
Moat scoreInsufficient evidence

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Halma is a UK-listed group of life-saving technology companies organised into Safety, Environmental & Analysis, and Healthcare. FY2026 revenue rose 15% to GBP2.582bn and adjusted EBIT rose 22% to GBP594.5m, with growth across all sectors. Current segment disclosures describe attractive regulated and high-value niches but do not quantify certification exclusivity, qualification duration, retention, switching costs or superior lifecycle economics, so no segment-level moat is recorded. Environmental & Analysis also carries material concentration risk: one long-standing hyperscaler customer represented about 20% of Group revenue. Halma acquired Dreampath Diagnostics on July 7, 2026, adding pathology workflow capability to Healthcare without changing FY2026 shares. Key risks are customer concentration, acquisition execution, OEM competition and technology change.

Primary segment

Environmental & Analysis

Market structure

Competitive

Market share

HHI:

Coverage

3 segments · 7 tags

Updated 2026-07-12

Segments

Safety

Safety technologies (fire safety, public safety, worker safety, and protection of critical assets/infrastructure)

Revenue

36.7%

Structure

Competitive

Pricing

moderate

Share

Peers

CARRHONJCISIE.DE+1

Environmental & Analysis

Environmental monitoring and analysis instruments (water/resource quality, pollution monitoring) plus materials/optoelectronic analysis and photonics components

Revenue

40.2%

Structure

Competitive

Pricing

moderate

Share

Peers

ADHRIEXKEYS+1

Healthcare

Healthcare technologies and medical devices (diagnostics, patient monitoring/analytics, surgical/therapeutic tools, and components sold to medical device OEMs)

Revenue

23.2%

Structure

Competitive

Pricing

moderate

Share

Peers

ABTBAXBSXMDT+1

Moat Claims

Safety

Safety technologies (fire safety, public safety, worker safety, and protection of critical assets/infrastructure)

FY2026 (year ended 31 Mar 2026): sector revenue GBP 947.5m and sector adjusted profit GBP 253.6m before allocation of adjustments. Shares use sector revenue total before immaterial inter-segment elimination and sector adjusted profit. Safety revenue rose 5.0% reported and 6.5% organic; adjusted profit margin rose to 26.8%.

Competitive

Insufficient segment-specific evidence to assign a moat claim.

Environmental & Analysis

Environmental monitoring and analysis instruments (water/resource quality, pollution monitoring) plus materials/optoelectronic analysis and photonics components

FY2026 (year ended 31 Mar 2026): sector revenue GBP 1.0377B and sector adjusted profit GBP 250.6m before allocation of adjustments. Shares use sector revenue total before immaterial inter-segment elimination and sector adjusted profit. Revenue rose 33.6%, driven by Optical Solutions/photonics premium growth; one hyperscaler customer represented 20% of Group revenue.

Competitive

Insufficient segment-specific evidence to assign a moat claim.

Healthcare

Healthcare technologies and medical devices (diagnostics, patient monitoring/analytics, surgical/therapeutic tools, and components sold to medical device OEMs)

FY2026 (year ended 31 Mar 2026): sector revenue GBP 598.4m and sector adjusted profit GBP 143.1m before allocation of adjustments. Shares use sector revenue total before immaterial inter-segment elimination and sector adjusted profit. Healthcare revenue rose 4.9% reported and 6.3% organic, with adjusted profit margin up 100 bps to 23.9%. Halma acquired Dreampath Diagnostics on 7 July 2026; the standalone Healthcare business is not reflected in FY2026 shares.

Competitive

Insufficient segment-specific evidence to assign a moat claim.

Evidence

No evidence sources linked yet.

Risks & Indicators

Erosion risks

No risks listed yet.

Leading indicators

No indicators listed yet.

Keep the research going

Created 2026-01-02
Updated 2026-07-12

More Rankings & Systems

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.